

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

**ANNOUNCEMENT ON THE CHANGE IN THE SHAREHOLDING STRUCTURE OF THE
COMPANY'S CONTROLLING SHAREHOLDER**

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Company has received a notice entitled "Notice regarding Change in Shareholding Structure of Tianjin Pharmaceutical Holdings Co., Ltd." (关于医药集团股权结构变更的通知函) (the "**Notice**") from its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) ("**TPH**"), stating that there is a change in the shareholding structure of TPH, and TPH has completed the relevant industrial and commercial modification registration formalities in respect of such change. Further details are set out below.

1. Change in the shareholding structure of TPH

Tianjin Bohai Guoxin Technology Co., Ltd. (天津渤海国鑫科技有限公司) ("**Bohai Guoxin**") is a wholly-owned subsidiary of Tianjin Bohai State-owned Assets Management Co., Ltd. (天津渤海国有资产经营管理有限公司) ("**Bohai State-owned Assets Management**"), and Bohai State-owned Assets Management held 33% equity interest in TPH prior to the Change (as defined below).

As stated in the Notice, Bohai State-owned Assets Management has subscribed for additional capital contributions in Bohai Guoxin with the 23% equity interest held by it in TPH and accordingly, as at the date of this announcement, Bohai Guoxin has become a shareholder of TPH and holds 23% equity interest in TPH, and Bohai State-owned Assets Management holds the remaining 10% equity interest in TPH (the "**Change**"). TPH has, on 4 August 2023, completed the industrial and commercial modification registration formalities in respect of the Change. Subsequently, Bohai State-owned Assets Management plans to continue to subscribe for additional capital contributions in Bohai Guoxin with its remaining 10% equity interest in TPH. Upon the subsequent subscription of capital contributions is completed, Bohai Guoxin will hold an aggregate of 33% equity interest in TPH, and Bohai State-owned Assets Management will cease to be a shareholder of TPH.

The shareholding structure of TPH before and after the Change is as follows:

Before the Change			After the Change		
No.	Name of shareholder	Shareholding ratio	No.	Name of shareholder	Shareholding ratio
1	Jinhushen Biological Medical Science and Technology Co., Ltd (津沪深生物医药科技有限公司)	67%	1	Jinhushen Biological Medical Science and Technology Co., Ltd (津沪深生物医药科技有限公司)	67%
2	Bohai State-owned Assets Management	33%	2	Bohai Guoxin	23%
			3	Bohai State-owned Assets Management	10%
Total		100%	Total		100%

2. Impact of the Change on the Company

The Change will not result in any change to the number of shares or the shareholding percentage held by TPH in the Company, nor will it result in any change in the controlling shareholder and/or the actual controller (as determined in accordance with the laws of the People's Republic of China (the "PRC")) of the Company. For the avoidance of doubt, TPH will remain as the controlling shareholder of the Company, and the Company will still have no actual controller (as determined in accordance with the laws of the PRC). In addition, the Change would not affect the normal operating activities of the Company.

3. Document for inspection

A copy of the Notice may be inspected at the registered office of the Company at 17 Baidi Road, Nankai District, Tianjin, the PRC, during normal business hours.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
4 August 2023